Impact of gastro-oesophageal reflux disease on work productivity despite therapy with proton pump inhibitors in Germany
- PMID: 20452898
- PMCID: PMC3352219
- DOI: 10.1186/2047-783x-15-3-124
Impact of gastro-oesophageal reflux disease on work productivity despite therapy with proton pump inhibitors in Germany
Abstract
Background: Gastro-oesophageal reflux disease (GERD) is a common disorder with consequences for the patient's health-related quality of life (HRQoL). In Germany, few data are available on the impact of GERD on work-related productivity.
Aim: To study the impact of GERD on work productivity despite proton pump inhibitor (PPI) therapy and the association between productivity and symptom duration, severity, and HRQoL.
Methods: Retrospective data from randomly selected patients with chronic GERD symptoms, treated by office-based general practitioners or general internists with routine clinical care, were analyzed together with information from self-administered instruments assessing work productivity (WPAI-GERD), symptoms (RDQ), and HRQoL (QOLRAD).
Results: Reduced productivity was reported by 152 of 249 patients (61.0%), although 89.5% of them were treated with PPI. The reduction in work productivity was 18.5% in all patients and 30.3% in those with reduced productivity. Patients with impaired productivity showed a significantly lower HRQoL and more-severe symptoms of reflux disease. In all patients, the mean sick leave attributable to reflux symptoms was 0.6 hours in the previous seven days and 1.4 work days in the previous three months.
Conclusion: GERD has a substantial impact on work productivity in Germany, even in patients receiving routine clinical care and PPI therapy.
Similar articles
-
Burden of gastro-oesophageal reflux disease in patients with persistent and intense symptoms despite proton pump inhibitor therapy: A post hoc analysis of the 2007 national health and wellness survey.Clin Drug Investig. 2011 Oct 1;31(10):703-15. doi: 10.2165/11595480-000000000-00000. Clin Drug Investig. 2011. PMID: 21756007
-
Cost and burden of gastroesophageal reflux disease among patients with persistent symptoms despite proton pump inhibitor therapy: an observational study in France.BMC Gastroenterol. 2013 Feb 28;13:39. doi: 10.1186/1471-230X-13-39. BMC Gastroenterol. 2013. PMID: 23448382 Free PMC article.
-
Validity of a Work Productivity and Activity Impairment questionnaire for patients with symptoms of gastro-esophageal reflux disease (WPAI-GERD)--results from a cross-sectional study.Value Health. 2002 Mar-Apr;5(2):106-13. doi: 10.1046/j.1524-4733.2002.52101.x. Value Health. 2002. PMID: 11918826
-
Review article: impact of night-time reflux on lifestyle - unrecognized issues in reflux disease.Aliment Pharmacol Ther. 2004 Dec;20 Suppl 9:3-13. doi: 10.1111/j.1365-2036.2004.02237.x. Aliment Pharmacol Ther. 2004. PMID: 15527460 Review.
-
Management of gastro-oesophageal reflux disease symptoms that do not respond to proton pump inhibitors.Curr Opin Gastroenterol. 2013 Jul;29(4):431-6. doi: 10.1097/MOG.0b013e328360433c. Curr Opin Gastroenterol. 2013. PMID: 23549342 Review.
Cited by
-
Constipation severity is associated with productivity losses and healthcare utilization in patients with chronic constipation.United European Gastroenterol J. 2014 Apr;2(2):138-47. doi: 10.1177/2050640614528175. United European Gastroenterol J. 2014. PMID: 24953097 Free PMC article.
-
Phase 4 Study in Patients From Asia With Gastroesophageal Reflux Disease Treated With Dexlansoprazole.J Neurogastroenterol Motil. 2020 Jan 30;26(1):85-95. doi: 10.5056/jnm19031. J Neurogastroenterol Motil. 2020. PMID: 31597230 Free PMC article.
-
A Meta-Analysis and Systematic Review of the Efficacy of Twice Daily PPIs versus Once Daily for Treatment of Gastroesophageal Reflux Disease.Gastroenterol Res Pract. 2017;2017:9865963. doi: 10.1155/2017/9865963. Epub 2017 Aug 22. Gastroenterol Res Pract. 2017. PMID: 28912807 Free PMC article. Review.
-
Surgical Treatment for Gastroesophageal Reflux Disease: Is It Effective Even for Asians?J Neurogastroenterol Motil. 2019 Jul 1;25(3):337-339. doi: 10.5056/jnm19127. J Neurogastroenterol Motil. 2019. PMID: 31327216 Free PMC article. No abstract available.
-
Efficacy of Endoscopic and Surgical Treatments for Gastroesophageal Reflux Disease: A Systematic Review and Network Meta-Analysis.J Pers Med. 2022 Apr 12;12(4):621. doi: 10.3390/jpm12040621. J Pers Med. 2022. PMID: 35455737 Free PMC article. Review.
References
-
- Willich SN, Nocon M, Kulig M, Jaspersen D, Labenz J, Meyer-Sabellek W, Stolte M, Lind T, Malfertheiner P. Cost-of-disease analysis in patients with gastro-oesophageal reflux disease and Barrett's mucosa. Aliment Pharmacol Ther. 2006;23(3):371–376. doi: 10.1111/j.1365-2036.2006.02763.x. - DOI - PubMed
-
- Kulig M, Leodolter A, Vieth M, Schulte E, Jaspersen D, Labenz J, Lind T, Meyer-Sabellek W, Malfertheiner P, Stolte M, Willich SN. Quality of life in relation to symptoms in patients with gastro-oesophageal reflux disease--an analysis based on the ProGERD initiative. Aliment Pharmacol Ther. 2003;18(8):767–776. doi: 10.1046/j.1365-2036.2003.01770.x. - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical